Hematological and nonhematological toxicities of imatinib mesylate in patients with chronic myeloid leukemia and gastrointestinal stromal tumor

  title={Hematological and nonhematological toxicities of imatinib mesylate in patients with chronic myeloid leukemia and gastrointestinal stromal tumor},
  author={Mohammad Usman and Naveen Naz Syed and Ghulam Nabi Kakepoto and Salman Naseem Adil and Mohammad Khurshid},
  journal={Indian Journal of Pharmacology},
Objectives : To determine the hematological and nonhematological toxicities of imatinib mesylate in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) and to review the literature to compile a list of the etiologic agents responsible for these events. Materials and Methods : This was a prospective study conducted from May 2001 to February, 2007. Two hundred and thirty-two patients with CML and GIST treated with imatinib mesylate at the Aga Khan University… 

Tables from this paper

Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate.

The case of a subdural hematoma occurring in a patient treated with adjuvant Imatinib for a high risk localized gastric GIST is presented.

Third‐line chemotherapy with tyrosine kinase inhibitor (imatinib mesylate) in recurrent ovarian granulosa cell tumor: Case report

A 60‐year‐old woman with a heavily pretreated recurrent, c‐kit positive, GCT of the ovary who underwent an experimental therapy with imatinib, a tyrosine kinase inhibitor, revealing a marked reduction of disease after 6’months of treatment is reported.

Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature

Despite the fact that almost all patients treated with a TKI experienced side effects, this did not seem to affect overall HRQoL during TKI therapy, suggesting that the reported side effects were underestimated by physicians.

Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.

Around one-third of patients with unresectable and/or metastatic GIST, who fail on 400 mg/day of imatinib, may show response or SD with escalated doses, and between a threshold of £25,000 and £45,000, provision of an escalated dose of Imatinib would be most likely to be cost-effective.



Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.

Several patients acquired additional clonal cytogenetic abnormalities during therapy, a finding with significant implications for prognosis and laboratory monitoring in imatinib mesylate-treated CML patients.

Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.

It is concluded that imatinib mesylate is a safe and effective first-line therapy for chronic myeloid leukemia.

Hypopigmentation in an African patient treated with imatinib mesylate: a case report.

A black Nigerian male with GIST, who developed hypopigmentation of distal parts of digits, as well as generalized lightening of skin on the body three months after receiving imatinib mesylate is reported.

The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.

Preliminary data suggest that the incidence of complete cytogenetic remission may exceed 60% in previously untreated patients, though its capacity to prolong life in comparison with other agents has not yet been clearly established.

Imatinib treatment: specific issues related to safety, fertility, and pregnancy.

With longer follow-up and with further experience with the treatment of patients outside of clinical trials, the identification of certain predictors of common toxicities, and the clinical experience with male fertility and pregnancy outcomes are reported.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

It is recommended that the preferred initial treatment for most patients newly diagnosed in chronic phase should now be 400 mg IM daily and the value of IM (400 mg/day) and of conventional allogeneic hematopoietic stem cell transplantation (alloHSCT) is confirmed.

Imatinib mesylate in chronic myeloid leukemia.

The current tools for the effective management of chronic myeloid leukemia with Imatinib are discussed, providing the updated results of IRIS and RIGHT clinical trials and then the suggestions how ImatinIB-treated patients should be monitored.

Clonal evolution in chronic myelogenous leukemia.

Natural history and staging of chronic myelogenous leukemia.

  • J. Cortes
  • Medicine
    Hematology/oncology clinics of North America
  • 2004

Practical management of patients with chronic myeloid leukemia receiving imatinib.

Practical guidelines in regard to optimal dosing, monitoring, managing common side effects such as myelosuppression, and potential drug interactions are reviewed.